Breast Cancer
Studies from M. Lidgren et al add new findings in the area of breast cancer
Published in Cancer Weekly, April 29th, 2008
"Clinical studies have demonstrated statistically significant reduction of breast cancer relapse and improved overall survival by adding trastuzumab for 1 year after adjuvant chemotherapy in human epidermal growth factor receptor-2 protein (HER2)/neu-positive breast cancer. The aim of this study was to analyze the cost-effectiveness of HER2/neu testing and the addition of 1-year adjuvant trastuzumab after adjuvant chemotherapy from a societal perspective in a Swedish setting," researchers in Stockholm, Sweden report.
"We used a Markov state transition model to simulate HER2/neu testing and adjuvant trastuzumab treatment in a hypothetical cohort of early breast cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-04-29)
More Articles from Cancer Weekly
- Angiogenesis
Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs from Fractionated Radiation; Reduces Angiogenesis and Inflammation - Breast Cancer
New Study Further Supports Safety of Promensil(R) as a Natural, Effective Way to Manage Mild-to-Moderate Menopausal Symptoms - Cancer
Cancer Matters Resource Guide Helps Charlotte-Area Residents Identify Local Cancer-Care Resources - Cancer
Cancer Matters Resource Guide Helps Cincinnati-Area Residents Identify Local Cancer-Care Resources - Cancer Gene Therapy
Data on cancer gene therapy discussed by researchers at University of Oxford - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at University of Munich - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
